Cargando…

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors

BACKGROUND: In developing countries, children with hemophilia A (HA) with high‐titer inhibitor and poor immune tolerance induction (ITI) prognostic risk(s) cannot afford the recommended high‐ or intermediate‐dose ITI. OBJECTIVES: To determine the efficacy of low‐dose ITI (plasma‐derived factor VIII...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zekun, Chen, Zhenping, Liu, Guoqing, Cheng, Xiaoling, Yao, Wanru, Huang, Kun, Li, Gang, Zhen, Yingzi, Wu, Xinyi, Cai, Siyu, Poon, Man‐Chiu, Wu, Runhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279128/ https://www.ncbi.nlm.nih.gov/pubmed/34278191 http://dx.doi.org/10.1002/rth2.12562

Ejemplares similares

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations
por: Li, Zekun, et al.
Publicado: (2020)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
por: Xu, Qian, et al.
Publicado: (2023)

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
por: Liu, Guoqing, et al.
Publicado: (2023)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
por: Huang, Kun, et al.
Publicado: (2022)

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
por: Sun, Jie, et al.
Publicado: (2022)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china
por: Wu, Runhui, et al.
Publicado: (2012)

Clinical Care of Bone Health in Patients on the Immune Tolerance Induction’s Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia
por: Rezaieyazdi, Zahra, et al.
Publicado: (2020)

Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A
por: Huang, Kun, et al.
Publicado: (2022)

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?
por: Poon, Man-Chiu, et al.
Publicado: (2016)

Acquired Hemophilia Successfully Treated With Oral Immunosuppressive Therapy
por: Lee, Je Jung, et al.
Publicado: (2000)

The Treatment of Acquired Hemophilia with Combination Therapy of Immunosuppressives and Immunoadsorption
por: Uğur Bilgin, Aynur, et al.
Publicado: (2014)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

Immune tolerance induction in patients with severe hemophilia A with inhibitors
por: Ryu, Ji Eun, et al.
Publicado: (2015)

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study
por: Cheng, Xiaoling, et al.
Publicado: (2019)

Immunosuppression Therapy in Acquired Hemophilia A: Pursuing an Optimal Regimen
por: Teixeira Passos, Dúlio, et al.
Publicado: (2021)

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
por: Herzog, Roland W., et al.
Publicado: (2017)

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
por: Jackson, Shannon C, et al.
Publicado: (2015)

P1619: LOME PILOT STUDY: A MULTICENTER CONTROLLED RANDOMIZED CLINICAL TRIAL OF LOW- VERSUS INTERMEDIATE-DOSE IMMUNE TOLERANCE INDUCTION WITH RECOMBINANT FACTOR VIII (OMFILOCTOCOG ALFA, SCT800) IN CHINA
por: LI, Zengping, et al.
Publicado: (2023)

T2 mapping in the quantitative evaluation of articular cartilage changes in children with hemophilia: A pilot study
por: Zhang, Ningning, et al.
Publicado: (2019)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
por: Liu, Wei, et al.
Publicado: (2022)

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis
por: Oomen, Ilja, et al.
Publicado: (2022)

A novel mutation in GP1BA gene in a family with autosomal dominant Bernard Soulier syndrome variant: A case report
por: Ma, Jingyao, et al.
Publicado: (2021)

Impact of the Induction of Labor on Hemophilia Carriers and Their Newborn Infants
por: Shibahara, Mami, et al.
Publicado: (2021)

Combining Low-Dose Rituximab and Bortezomib as Immunosuppressive Therapy for Acquired Hemophilia A: 6 Case Series
por: Fu, Yuhan, et al.
Publicado: (2023)

Immunosuppression and immunological tolerance induction: lessons from a transplant model
por: Filatenkov, A, et al.
Publicado: (2003)

Comprehensive Comparison of Three Different Immunosuppressive Regimens for Liver Transplant Patients with Hepatocellular Carcinoma: Steroid-Free Immunosuppression, Induction Immunosuppression and Standard Immunosuppression
por: Liu, Yuan-Yuan, et al.
Publicado: (2015)

An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform
por: Katayama, Haruna, et al.
Publicado: (2018)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
por: Dobbelstein, Christiane, et al.
Publicado: (2020)

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gelrqtja9f2eugjf4kk6rht3jk